Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093)

Organon and Co190 enrolled

Overview

An efficacy and safety study of ezetimibe (+) simvastatin compared to atorvastatin at week 6 in diabetics or metabolic syndrome patients in Korea.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

190

Conditions

Hypercholesterolemia

Interventions

simvastatin (+) ezetimibeDRUG

simvastatin (+) ezetimibe 10/20mg.

atorvastatinDRUG

atorvastatin 10mg

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of hypercholesterolemia * Drug naive or statin treated but inadequately controlled patients against NCEP ATP III guideline goal Exclusion Criteria: * Hypersensitivity to HMG-CoA inhibitor or Ezetimibe

Outcomes

Primary Outcomes

LDL-C lowering efficacy

Time frame: 6 weeks

Secondary Outcomes

Safety

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.